Search Results - "WAHREN, B"

Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity by Latanova, A. A., Petkov, S., Kilpelainen, A., Jansons, J., Latyshev, O. E., Kuzmenko, Y. V., Hinkula, J., Abakumov, M. A., Valuev-Elliston, V. T., Gomelsky, M., Karpov, V. L., Chiodi, F., Wahren, B., Logunov, D. Y., Starodubova, E. S., Isaguliants, M. G.

“…DNA vaccines require a considerable enhancement of immunogenicity. Here, we optimized a prototype DNA vaccine against drug-resistant HIV-1 based on a weak…”
Get full text

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses by Stenler, S., Lundin, K. E., Hansen, L., Petkov, S., Mozafari, N., Isaguliants, M., Blomberg, P., Smith, C. I. E., Goldenberg, D. M., Chang, C.-H., Ljungberg, K., Hinkula, J., Wahren, B.

“…Background: Genetic immunization is expected to induce the expression of antigens in a native form. The encoded peptide epitopes are presented on endogenous…”
Get full text

DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity by Buonaguro, L, Devito, C, Tornesello, M.L, Schröder, U, Wahren, B, Hinkula, J, Buonaguro, F.M

“…Abstract The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal…”
Get full text

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial by Gudmundsdotter, L, Wahren, B, Haller, B.K, Boberg, A, Edbäck, U, Bernasconi, D, Buttò, S, Gaines, H, Imami, N, Gotch, F, Lori, F, Lisziewicz, J, Sandström, E, Hejdeman, B

“…Abstract Immunotherapy in patients with HIV-1 infection aims to restore and broaden immunological competence, reduce viral load and thereby permit longer…”
Get full text

The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children by Palma, P, Foster, C, Rojo, P, Zangari, P, Yates, A, Cotugno, N, Klein, N, Luzuriaga, K, Pahwa, S, Nastouli, E, Gibb, DM, Borkowsky, W, Bernardi, S, Calvez, V, Manno, E, Mora, Nadia, Compagnucci, A, Wahren, B, Muñoz-Fernández, MÁ, De Rossi, A, Ananworanich, J, Pillay, D, Giaquinto, C, Rossi, P

“…The EPIICAL (Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies) project arises from…”
Get full text

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV by Hinkula, J, Petkov, S, Ljungberg, K, Hallengärd, D, Bråve, A, Isaguliants, M, Falkeborn, T, Sharma, S, Liakina, V, Robb, M, Eller, M, Moss, B, Biberfeld, G, Sandström, E, Nilsson, C, Markland, K, Blomberg, P, Wahren, B

“…In order to develop a more effective prophylactic HIV-1 vaccine it is important optimize the components, improve Envelope glycoprotein immunogenicity as well…”
Get full text

Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin by Boberg, A, Gaunitz, S, Bråve, A, Wahren, B, Carlin, N

“…Abstract As more HIV-1 infected patients receive anti-retroviral drug treatment, the occurrence of drug-resistant variants of the virus is increasing. We have…”
Get full text

Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression by Stenler, Sofia, Wiklander, Oscar PB, Badal-Tejedor, Maria, Turunen, Janne, Nordin, Joel Z, Hallengärd, David, Wahren, Britta, Andaloussi, Samir EL, Rutland, Mark W, Smith, CI Edvard, Lundin, Karin E, Blomberg, Pontus

“…The minicircle (MC), composed of eukaryotic sequences only, is an interesting approach to increase the safety and efficiency of plasmid-based vectors for gene…”
Get full text

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue by Zou, L.-P., Abbas, N., Volkmann, I., Nennesmo, I., Levi, M., Wahren, B., Winblad, B., Hedlund, G., Zhu, J.

“…The therapeutic effects of ABR-215062, which is a new immunoregulator derived from Linomide, have been evaluated in experimental autoimmune neuritis (EAN), a…”
Get full text

Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles by Gudmundsdotter, L, Bernasconi, D, Hejdeman, B, Sandstrom, E, Alaeus, A, Lidman, K, Ensoli, B, Wahren, B, Buttò, S

“…Abstract Individuals infected with different subtypes of HIV-1 (A, B, C, D, CRF01_AE and CRF02_AG) were analyzed for their antigen-specific immune response…”
Get full text

Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies by ROLLMAN, E, HINKULA, J, ARTEAGA, J, ZUBER, B, KJERRSTRÖM, A, LIU, M, WAHREN, B, LJUNGBERG, K

“…A highly desirable feature for an human immunodeficiency virus type 1 (HIV-1) vaccine is the ability to induce broadly reactive anti-envelope antibodies that…”
Get full text

P19-29. Determining the optimal protocol for plasmid DNA vaccine delivery by intradermal in vivo electroporation by Hallengard, D, Brave, A, Roos, A, Gelius, E, Nihlmark, K, Wahren, B

Get full text

HIV in Europe — a growing threat by Wahren, B.

Get full text

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults by Joachim, A, Nilsson, C, Aboud, S, Lyamuya, EF, Robb, M, Marovich, M, Ochsenbauer, C, Wahren, B, Sandström, E, Biberfeld, G, Ferrari, G, Polonis, VR

“…Doc number: O53…”
Get full text

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen by Makitalo, B, Lundholm, P, Hinkula, J, Nilsson, C, Karlen, K, Morner, A, Sutter, G, Erfle, V, Heeney, J. L, Wahren, B, Biberfeld, G, Thorstensson, R

“…1 Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden 2 Microbiology and Tumor Biology Center, Karolinska Institute, Sweden 3 Institute…”
Get full text

60 Years of viral vaccines Britta Wahren by Wahren, B

Get full text

The rationale behind a vaccine based on multiple HIV antigens by Rollman, E., Bråve, A., Boberg, A., Gudmundsdotter, L., Engström, G., Isaguliants, M., Ljungberg, K., Lundgren, B., Blomberg, P., Hinkula, J., Hejdeman, B., Sandström, E., Liu, M., Wahren, B.

“…The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on…”
Get full text

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees by Nilsson, C, Aboud, S, Karlen, K, Marovich, M, Wahren, B, Sandstrom, E, Gaines, H, Biberfeld, G, Godoy-Ramirez, K

Get full text

Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer by Hallermalm, K, Johansson, S, Bråve, A, Ek, M, Engström, G, Boberg, A, Gudmundsdotter, L, Blomberg, P, Mellstedt, H, Stout, R, Liu, M.A, Wahren, B

“…In preparation for a clinical trial in patients diagnosed with colorectal cancer, a vaccination strategy targeting the carcinoembryonic antigen (CEA) was…”
Get full text

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine by Munseri, P, Kroidl, A, Nilsson, C, Moshiro, C, Aboud, S, Joachim, A, Geldmacher, C, Aris, E, Buma, D, Lyamuya, E, Gotch, F, Godoy-Ramirez, K, Pallangyo, K, Maboko, L, Marovich, M, Robb, M, Hoelscher, M, Janabi, M, Mann, P, Joseph, S, Mfinanga, S, Stoehr, W, Mhalu, F, Wahren, B, Biberfeld, G, McCormack, S, Sandstrom, E, Bakari, M

“…Doc number: P108…”
Get full text